Related Experiment Video
Updated: May 19, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Extended Half-Life Factor Concentrates in Haemophilia Treatment
Katharina Holstein1,2, Tido Bajorat1, Rafael Beck1,3
1Coagulation Centre, Institute for Clinical Chemistry, University Medical Centre Schleswig-Holstein, Kiel, Germany.
Summary
Extended half-life (EHL) factor concentrates offer improved prophylaxis for haemophilia A and B, reducing bleeds and treatment burden. These advanced therapies enhance joint health and quality of life compared to standard treatments.
Area of Science:
- Hematology
- Pharmacology
- Biotechnology
Background:
- Prophylaxis is crucial for preventing musculoskeletal bleeds in severe and moderate haemophilia A (HA) and B (HB).
- Standard half-life (SHL) clotting factors require frequent infusions, increasing patient treatment burden.
- Extended half-life (EHL) factor concentrates and non-factor therapies (NFT) were developed to address these limitations.
Purpose of the Study:
- To review current knowledge on extended half-life (EHL) factor concentrates for haemophilia A and B.
- To summarize the mechanisms, clinical benefits, and safety considerations of EHL therapies.
Main Methods:
- Review of literature on EHL factor concentrates, including fragment crystallizable (Fc) fusion, albumin fusion, and PEGylation technologies.
- Analysis of clinical trial data and real-world evidence on EHL efficacy and safety.
- Examination of specific challenges in extending the half-life of factor VIII (FVIII).
Main Results:
- EHL concentrates utilize various technologies to prolong half-life and reduce clearance.
- Clinical data demonstrate reduced annualized bleed rates (ABRs), improved joint health, and enhanced patient quality of life with EHL therapies.
- While generally safe, PEGylated products require ongoing pharmacovigilance due to theoretical concerns.
Conclusions:
- EHL factor concentrates provide effective and safe prophylaxis and treatment for haemophilia, offering clinical benefits over SHL products.
- These therapies allow for less frequent administration, improving adherence and reducing treatment burden.
- EHL treatments represent a significant advancement in haemophilia management, coexisting with non-factor therapies.
Related Concept Videos
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
02:42Half-life of a Reaction
The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:14Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...